These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 17968710

  • 21. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
    Han B, Tong J, Zhu MJ, Ma C, Du M.
    Mol Reprod Dev; 2008 May; 75(5):810-7. PubMed ID: 18033679
    [Abstract] [Full Text] [Related]

  • 22. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 23. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway.
    Dayan F, Bilton RL, Laferrière J, Trottier E, Roux D, Pouyssegur J, Mazure NM.
    J Cell Physiol; 2009 Jan; 218(1):167-74. PubMed ID: 18781596
    [Abstract] [Full Text] [Related]

  • 24. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells.
    Aleffi S, Navari N, Delogu W, Galastri S, Novo E, Rombouts K, Pinzani M, Parola M, Marra F.
    Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G210-9. PubMed ID: 21252047
    [Abstract] [Full Text] [Related]

  • 25. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
    Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O.
    Int J Cancer; 2007 Apr 15; 120(8):1803-10. PubMed ID: 17230506
    [Abstract] [Full Text] [Related]

  • 26. mTOR and P70 S6 kinase expression in primary liver neoplasms.
    Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M.
    Clin Cancer Res; 2004 Dec 15; 10(24):8421-5. PubMed ID: 15623621
    [Abstract] [Full Text] [Related]

  • 27. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E, Salvadori M.
    J Nephrol; 2009 Dec 15; 22(4):457-62. PubMed ID: 19662600
    [Abstract] [Full Text] [Related]

  • 28. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.
    Brain; 2009 Jun 15; 132(Pt 6):1509-22. PubMed ID: 19416948
    [Abstract] [Full Text] [Related]

  • 29. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
    Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG, Abraham RT.
    Cancer Res; 2005 Jun 15; 65(12):5325-36. PubMed ID: 15958580
    [Abstract] [Full Text] [Related]

  • 30. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer.
    Fechner G, Classen K, Schmidt D, Hauser S, Müller SC.
    Urology; 2009 Mar 15; 73(3):665-8; discussion 668-9. PubMed ID: 19081609
    [Abstract] [Full Text] [Related]

  • 31. An expanding role for mTOR in cancer.
    Guertin DA, Sabatini DM.
    Trends Mol Med; 2005 Aug 15; 11(8):353-61. PubMed ID: 16002336
    [Abstract] [Full Text] [Related]

  • 32. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
    Sun MM, Zhang MZ, Chen Y, Li SL, Zhang W, Ya GW, Chen KS.
    J Int Med Res; 2012 Aug 15; 40(5):1636-43. PubMed ID: 23206445
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.
    Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC.
    Mol Carcinog; 2008 Sep 15; 47(9):686-700. PubMed ID: 18240292
    [Abstract] [Full Text] [Related]

  • 34. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK, Srdić T, Radulović S.
    J BUON; 2006 Sep 15; 11(3):267-76. PubMed ID: 17309148
    [Abstract] [Full Text] [Related]

  • 35. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif.
    Land SC, Tee AR.
    J Biol Chem; 2007 Jul 13; 282(28):20534-43. PubMed ID: 17502379
    [Abstract] [Full Text] [Related]

  • 36. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.
    Cancer Res; 2008 Apr 15; 68(8):2934-43. PubMed ID: 18413763
    [Abstract] [Full Text] [Related]

  • 37. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
    Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, Dufour JF.
    J Hepatol; 2007 May 15; 46(5):840-8. PubMed ID: 17321636
    [Abstract] [Full Text] [Related]

  • 38. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 May 15; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 39. Rapamycin induces Smad activity in prostate cancer cell lines.
    van der Poel HG, Hanrahan C, Zhong H, Simons JW.
    Urol Res; 2003 Feb 15; 30(6):380-6. PubMed ID: 12599018
    [Abstract] [Full Text] [Related]

  • 40. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 15; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.